Navigation Links
Regenicin Presentation Now Available Online at

NEW YORK, Nov. 5, 2010 /PRNewswire/ -- Regenicin, Inc. (OTC Bulletin Board: WDST) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, today announced that their November 4th investor presentation is available for archive viewing.


Regenicin's presentation will be available for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three weeks.

The Regenicin presentation, which was given by CEO, Randall McCoy and CFO, John Weber, provides an overview of Regenicin's role in the development of the product candidate, PermaDerm™, an exciting breakthrough technology that uses the patient's own skin cells to generate living, tissue-engineered skin for the treatment of chronic burns. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. These living self-to-self skin graft tissue are intended to form permanent skin that will grow with the patient and not be rejected by the immune system, a critical possibility in porcine or cadaver skin grafts used today.

About Regenicin

Regenicin, Inc., is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New York City.

About, created by BetterInvesting (NAIC), PR Newswire and MUNCmedia, is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network and MUNCmedia's sophisticated retail investor targeting.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
2. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
3. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
4. Regenicin to Form Scientific Advisory Board
5. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
6. Regenicin to Present Live at on November 4th
7. Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
9. Cepheid to Webcast Upcoming Financial Presentations
10. Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008
11. Volcano Presentation at Thomas Weisel Conference to Be Webcast
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... Mass. (PRWEB) , ... November 24, 2015 , ... ... to maintain healthy metabolism. But unless it is bound to proteins, copper is ... of Health (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
Breaking Biology Technology:
(Date:10/27/2015)... JOSE, Calif. , Oct. 27, 2015 Synaptics ... interface solutions, today announced that Google has adopted the ... of touch controller solutions to power its newest flagship ... 6P by Huawei. --> ... partners like Google to provide strategic collaboration in the ...
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
(Date:10/22/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics software ... September 30, 2015.  --> --> ... a decrease of 33% compared to $6.0 million in the same ... was $2.2 million, or $0.10 per diluted share, which compared to ... a year ago.  --> --> ...
Breaking Biology News(10 mins):